Get started
Author

Sungwoo Ahn

Observed institution: University of Calgary
ORCID: 0000-0002-7688-6843
Observed ORCID: 0000-0002-7688-6843
OpenAlex ID: A5035522733
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
2023 · Holly Lee, Sungwoo Ahn, et al. · Nature Medicine · 359
PDF
Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma
2024 · Holly Lee, Michael Durante, et al. · Blood · 85
PDF
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
2023 · Paola Neri, Benjamin G. Barwick, et al. · Blood Cancer Discovery · 35
Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency
2023 · Noémie Leblay, Sungwoo Ahn, et al. · Blood · 35
Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma
2021 · Sungwoo Ahn, Noémie Leblay, et al. · HemaSphere · 19
The Impact of Soluble BCMA and BCMA Gain on Anti-BCMA Immunotherapies in Multiple Myeloma
2023 · Holly Lee, Michael Durante, et al. · Blood · 15
Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
2023 · Yoon Tae Kim, Jin Won Huh, et al. · EMBO Molecular Medicine · 14
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
2026 · Holly Lee, Sungwoo Ahn, et al. · Nature Medicine · 13
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
2025 · Marios Papadimitriou, Sungwoo Ahn, et al. · Blood Cancer Discovery · 13
Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
2022 · Holly Lee, Paola Neri, et al. · Blood · 13
Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
2022 · Paola Neri, Sungwoo Ahn, et al. · Blood · 12
A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma
2021 · Ranjan Maity, Sacha Benaoudia, et al. · Blood · 11
Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance
2023 · Holly Lee, Sungwoo Ahn, et al. · Blood · 9
OAB-005: Point mutations in BCMA extracellular domain mediate resistance to BCMA targeting immune therapies
2022 · Holly Lee, Ranjan Maity, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers
2025 · Holly Lee, Sungwoo Ahn, et al. · Blood · 4
PDF
NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
2024 · David Jung, Holly Lee, et al. · Blood · 4
Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells
2023 · Mansour Poorebrahim, Holly Lee, et al. · Blood · 4
PDF
Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers
2021 · Mirco Friedrich, Paola Neri, et al. · Blood · 3
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
2025 · Francesco Maura, Ciara L. Freeman, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
Author Correction: Highly secreted tryptophanyl tRNA synthetase 1 as a potential theranostic target for hypercytokinemic severe sepsis
2024 · Yoon Tae Kim, Jin Won Huh, et al. · EMBO Molecular Medicine · 2
Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
2024 · Marios Papadimitriou, Sungwoo Ahn, et al. · Blood · 1
Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
2024 · Noémie Leblay, Sungwoo Ahn, et al. · Blood · 1
Supplementary Tables S1-S2 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
2025 · Marios Papadimitriou, Sungwoo Ahn, et al.
Data from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
2025 · Marios Papadimitriou, Sungwoo Ahn, et al.
Supplementary Figures S1-S3 from Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
2025 · Marios Papadimitriou, Sungwoo Ahn, et al.
PDF
Works count: 78
Citation count: 658
H-index: 11
I10-index: 12
Year
Topic
Type